On an attempt to treat primary and secondary osteoporosis with human growth hormone.
Three male patients with severe osteoporosis were treated with human growth hormone. One of them had a primary osteoporosis, the two others osteogenesis imperfecta. The duration of therapy was 8 to 15 months and average doses per day were 1.45 to 2.3 mg. While clinical and 47calcium kinetic data failed to prove marked influences of the treatment, histomorphometry of bone biopsies showed indisputable changes. There was an increase of periosteal new bone formation as well as of intracortical bone resorption, while at the same time the relative activity of osteoblasts on endosteal surfaces showed a significant increase.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood / Q000652:urine; D005500:Follow-Up Studies; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010013:Osteogenesis Imperfecta / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000652:urine; D010758:Phosphorus / Q000097:blood / Q000652:urine
D010758:Phosphorus; D013006:Growth Hormone; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium